Molecular Templates CEO and leadership

Eric Poma, Ph.D. has served as Molecular Templates’ Chief Executive Officer and Chief Scientific Officer since the Company’s inception in 2009.From March 2005 until September 2008, Eric Poma was Vice President of Business Development of Innovive Pharmaceuticals (acquired by Cytrx Corporation), a biotechnology company. From 2001 to 2005, he served as the Associate Vice President of Business Development at ImClone Systems, Inc.(now Eli Lilly and Company) a biotechnology company focused on antibody therapeutics. As the founder and in his role as Chief Scientific Officer at MTEM, he led the invention of technology underlying MTEM’s platform technology and what constitutes the whole of MTEM’s current lead and preclinical pipeline candidates. Eric Poma received his Ph.D. in Microbiology and Immunology and B.A. in Biology and from the University of North Carolina at Chapel Hill and his M.B.A. from New York University.

Jason Kim joined Molecular Templates in 2010 and serves as President and Chief Operating Officer. He served as Molecular Templates’ President and Chief Financial Officer from February 2010 to August 2017. Previously, Jason Kim led corporate development and strategic planning initiatives at OSI Pharmaceuticals (acquired by Astellas) and ImClone Systems (acquired by Lilly). He served as an investment professional at Domain Associates and Safeguard Scientifics where he focused on venture and public investments in biotechnology. Jason Kim holds an MBA from The Wharton School and a BA in Neuroscience from Wesleyan University.

Roger Waltzman, MD, MBA joined Molecular Templates as Chief Medical Officer in February 2019. He is a board-certified medical oncologist with over 20 years of experience in the pharmaceutical and biotechnology industries, and in medical practice/academia.His career highlights include 9 years in senior drug development roles at Novartis Pharmaceuticals Corporation, including 6 years in positions of increasing responsibility at Novartis Oncology (2007–2013). He played a leading role in the development of highly successful Novartis branded oncology drugs, Glivec® (imatinib) and Jakafi®(ruxolitinib). His last role at Novartis was as Full Development Head of Malaria Drug Development (2013-16). More recently, Roger Waltzman was CMO at Rgenix, where he supervised the development of immuno-oncology and metabolic inhibitor assets through Phase 1 a/b. Previously, he served as CMO and CSO at Jaguar Health and Napo Pharmaceuticals, where he led scientific aspects of development and commercialization of Mytesi® (crofelemer) for patients with HIV and diarrhea, as well as development programs in chemotherapy-induced diarrhea and various indications for companion and production animals. Prior to joining industry, Roger Waltzman held assistant professorships in medical oncology and palliative care at Saint Vincent’s Hospital and Mount Sinai School of Medicine in New York. At Saint Vincent’s Hospital, he was responsible for overseeing oncology care for patients with breast, gastrointestinal, gynecologic, thoracic, and AIDS-related malignancies. He completed his fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center. Roger Waltzman earned an M.B.A. at Columbia Business School where he graduated valedictorian, an M.D. from Brown University School of Medicine and a B.A. from Brown University.

Eric Poma, Ph.D. has served as Molecular Templates’ Chief Executive Officer and Chief Scientific Officer since the Company’s inception in 2009.From March 2005 until September 2008, Eric Poma was Vice President of Business Development of Innovive Pharmaceuticals (acquired by Cytrx Corporation), a biotechnology company. From 2001 to 2005, he served as the Associate Vice President of Business Development at ImClone Systems, Inc.(now Eli Lilly and Company) a biotechnology company focused on antibody therapeutics. As the founder and in his role as Chief Scientific Officer at MTEM, he led the invention of technology underlying MTEM’s platform technology and what constitutes the whole of MTEM’s current lead and preclinical pipeline candidates. Eric Poma received his Ph.D. in Microbiology and Immunology and B.A. in Biology and from the University of North Carolina at Chapel Hill and his M.B.A. from New York University.